This study is looking at how people's immune systems react when they have early-stage Triple Negative Breast Cancer (TNBC) and receive a neoadjuvant chemo-immunotherapy. Neoadjuvant therapy means treatment is given before the main treatment. This study uses a chemo-immunotherapy called pembrolizumab. Pembrolizumab is a medicine that helps the immune system fight cancer. The aim is to check if this treatment creates a specific response in the body, making it more inflammatory, which might help kill cancer cells. They will also see if the treatment works by looking at the cancer tissue.

• The study requires regular visits for treatment and tests.
• Participants must not have had cancer treatment before joining.
• Participants will need to sign a consent form and follow study rules.

To join, you must have early-stage TNBC and meet specific health conditions. Pregnant or breastfeeding women, or those on certain medications cannot join. This research could help understand how well this treatment works and why some tumors might not respond. Participants should discuss with doctors to understand the potential benefits and risks.